SEC Form 4 · accession 0001127602-18-020831
HAEMONETICS CORP · HAE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Simon
Officer — President & CEO · Director
Period of report
Jun 11, 2018
Accepted (ET)
Jun 13, 2018 · 7:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000313143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Jun 11, 2018 | A | 11,361 | — | A | 138,265 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F4 | $93.52 | Jun 11, 2018 | A | 40,443 | A | — | Jun 11, 2025 | Common Stock | 40,443 | 40,443 | D |
Explanation of responses
- F1The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
- F2Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
- F3This number includes unvested restricted stock units previously reported.
- F4Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.